Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06149286 2026-05-06

OLYMPIA-5

Phase 3 Recruiting

470 enrolled

Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06793189 2026-03-24

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Phase 2 Recruiting

145 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT07448324 2026-03-04

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

Phase 2 Recruiting

50 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT04669171 2026-01-30

SIDNEY

Phase 1/2 Recruiting

80 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04792502 2025-12-30

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Phase 2 Recruiting

52 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Phase 3 Recruiting

260 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT07208981 2025-10-06

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Phase 2 Recruiting

169 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06082102 2025-09-15

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Phase 3 Recruiting

324 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06792825 2025-08-12

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Phase 2 Recruiting

65 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04110301 2024-11-20

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Phase 1/2 Recruiting

53 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06454968 2024-06-18

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05846750 2023-07-19

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Phase 2 Recruiting

59 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

Clinical Trials

MAHOGANY

OLYMPIA-5

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

SIDNEY

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma